Loading clinical trials...
Loading clinical trials...
An Open Label, Prospective and Multi-center Recurrence Prevention Study With Effexor XR in MDD Patients in China
This primary purpose of this study is to assess the efficacy and safety of Effexor XR in preventing recurrence in Chinese patients with recurrent major depressive disorder (MDD) following a 1-year maintenance treatment after an 8-week acute treatment and a 6-month continuation treatment phases. The study will also collect data on the prevalence and pattern of co-morbid anxiety and somatic symptoms and their impact on the recurrence of depression.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Start Date
April 1, 2009
Primary Completion Date
October 1, 2011
Completion Date
October 1, 2011
Last Updated
August 20, 2021
Effexor XR
DRUG
Effexor XR discontinue
OTHER
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
NCT07115329
NCT06793397
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07025720